New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 27, 2014
16:24 EDTLPCNLipocine announces first patient dosed in Phase 2a study of LPCN 1111
Lipocine announced that the first patient has been dosed in a Phase 2a clinical study of LPCN 1111, a novel ester prodrug of testosterone, in hypogonadal males. The primary objectives of the study will be to determine safety, tolerability, single and steady state pharmacokinetics of testosterone following oral administration of LPCN 1111.
News For LPCN From The Last 14 Days
Check below for free stories on LPCN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
11:15 EDTLPCNRepros sinks after panel backs tests for testosterone therapies
Subscribe for More Information
06:10 EDTLPCNFDA panel votes 20-1 to study changes to testosterone therapies
Subscribe for More Information
September 17, 2014
06:59 EDTLPCNLipocine trading halted, pending news
Subscribe for More Information
September 8, 2014
16:01 EDTLPCNLipocine announces first patient dosed in LPCN 1107 Phase 1 study
Lipocine announced the first patient was dosed in a Phase 1 study in pregnant women of LPCN 1107, the company's oral hydroxyprogesterone caproate, or HPC, product candidate. The primary objectives of the study will be to determine safety, tolerability and pharmacokinetics of oral administration of LPCN 1107 in pregnant subjects. Previously in Phase 1 clinical testing, LPCN 1107 was well tolerated and achieved meaningful drug levels after oral administration in healthy, non-pregnant women.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use